Anixa Biosciences Receives Approval for Non-Proprietary Name "Liraltagene Autoleucel" for CAR-T Therapy.

Anixa Biosciences announced the World Health Organization's approval of "liraltagene autoleucel" as the non-proprietary name for the company's FSHR-targeted CAR-T therapy for recurrent ovarian cancer. This represents an important step in the development and potential commercialization of the therapy, with the first-in-human trial currently enrolling adult women with recurrent ovarian cancer.